O2‐13‐06: Predicting Alzheimer's Disease From a Blood‐based Biomarker Profile: Results From Aipl at 54 Months
Year: 2014
Type: article
Study design: Observational Study
Abstract: A previous study 1 showed that a blood-based signature was able to estimate neocortical β-amyloid burden (NAB). We aimed to assess if this blood-based signature can accurately identify individuals at risk of progression to AD. The blood-based signature was generated for 585 healthy controls (HC) and 49 Mild Cognitively Impaired (MCI) participants who underwent clinical reclassification at 54-month follow-up (reclassification was blinded to biomarker findings). The individuals were split into Predicted PiB Positive (PPP) and Predicted PiB Negative (PPN) groups based on a cut off of 1.5. The predictive accuracy of the groupings was assessed based on disease progression as per clinical reclassification at 54-month follow-up. Seven percent of HC progressed to either (34) MCI or (7) AD, while 65% (32) of MCI progressed to probable AD within 54 months. Eleven percent of the HC-PPP group progressed within 54 months in comparison to 4% of the HC-PPN group (OR = 2.16, a Positive Predictive Value, PPV, of 10% and Negative Predictive Value, NPV, of 95%), Table 1. Eighty percent of the MCI-PPP group progressed within 54 months in comparison to 29% of the MCI-PPN group (OR = 10.00; PPV of 72% and NPV of 80%). The HC-PPP group had faster rates of episodic memory decline than the HC-PPN group, with the HC-PPP group estimated to reach clinically-significant memory impairment twice as fast as the HC-PPN group. The MCI-PPP group had faster rates of decline for episodic and semantic memory as well as clinical measures compared to the MCI-PPN group. The MCI-PPP group was estimated to reach average levels of AD impairment within 5-10 years compared with more than 20 years for the MCI-PPN group. Healthy control and MCI participants estimated to have high NAB from a published blood-based signature had a significantly higher chance of progressing to AD. This suggests that a simple blood-based signature not only provides estimates of NAB but also accurately identifies individuals at risk of progressing to AD at the prodromal and preclinical stages. 1 http://dx.doi.org/10.1038/mp.2013.40.
Source: Alzheimer s & Dementia
Authors: Samantha C. Burnham, David Ames, David Baker, Ashley I. Bush, Lynne Cobiac, James Doecke, Kathryn A. Ellis, Noel Garry Faux, Richard Head, Harri Kiiveri, Simon Matthew Laws, Ralph Martins, Paul Maruff, Greg Savage, Bill Wilson, Lance Macaulay, Christopher Cleon Rowe, Colin Louis Masters, Victor L. Villemagne
Institutions: Commonwealth Scientific and Industrial Research Organisation, National Ageing Research Institute, St George Hospital, Mental Health Research Institute, University of South Australia, Edith Cowan University, Macquarie University, Austin Hospital, Florey Institute of Neuroscience and Mental Health, Austin Health
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W1980613871